{
    "clinical_study": {
        "@rank": "85548", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab naive recurrent grade IV gliomas", 
                "arm_group_type": "Active Comparator", 
                "description": "27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression"
            }, 
            {
                "arm_group_label": "Bevacuzumab exposed and refractive grade IV gliomas", 
                "arm_group_type": "Active Comparator", 
                "description": "27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression"
            }, 
            {
                "arm_group_label": "Bevacizumab naive recurrent grade III gliomas", 
                "arm_group_type": "Active Comparator", 
                "description": "27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression"
            }, 
            {
                "arm_group_label": "Bevacizumab exposed and refractive grade III gliomas", 
                "arm_group_type": "Active Comparator", 
                "description": "27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27\n      fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until\n      time of progression in patients with recurrent high grade gliomas (grade III and grade IV).\n      Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior\n      exposure to bevacizumab."
        }, 
        "brief_title": "A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Glioma", 
        "condition_browse": {
            "mesh_term": "Glioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diagnose of a grade WHO grade III or IV glioma\n\n          -  Recurrent disease based on combination of clinical, imaging or histologic\n             confirmation\n\n          -  Must have previously received radiation and temozolomide to treat their glioma\n\n          -  Bevacizumab naive patients must be > 6months post completion of initial radiation\n             therapy\n\n          -  Bevacizumab exposed patients must be > 3months post completion of initial radiation\n             therapy\n\n          -  Age must be >18years, KPS must be greater than 60\n\n          -  Hematology, chemistry and a urinalysis  must meet protocol specified criteria\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding\n\n          -  May not be on full dose anti-coagulation therapy, Low molecular weight heparin is ok\n\n          -  Uncontrolled hypertension (>140/90mmHg)\n\n          -  Prior malignancy unless treated >1 year prior to study and have been  without\n             treatment and    disease free for 1 yr\n\n          -  active second malignancy unless non-melanoma skin cancer or cervical cancer in situ"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743950", 
            "org_study_id": "CO11374"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Bevacizumab naive recurrent grade IV gliomas", 
                    "Bevacuzumab exposed and refractive grade IV gliomas", 
                    "Bevacizumab naive recurrent grade III gliomas", 
                    "Bevacizumab exposed and refractive grade III gliomas"
                ], 
                "description": "10mg/kg every 2weeks.", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Bevacizumab naive recurrent grade IV gliomas", 
                    "Bevacuzumab exposed and refractive grade IV gliomas", 
                    "Bevacizumab naive recurrent grade III gliomas", 
                    "Bevacizumab exposed and refractive grade III gliomas"
                ], 
                "description": "daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions", 
                "intervention_name": "PRDR", 
                "intervention_type": "Radiation", 
                "other_name": "re-irradiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glioblastoma", 
            "anaplastic glioma"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53792"
                }, 
                "name": "University of Wisconsin Hospital and Clinics"
            }, 
            "investigator": [
                {
                    "last_name": "Steve Howard, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "H. Ian Robins, MD, Ph.D", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "trask@humonc.wisc.edu", 
            "last_name": "Diana Trask, BS", 
            "phone": "608-263-9528"
        }, 
        "overall_contact_backup": {
            "email": "anger@humonc.wisc.edu", 
            "last_name": "Nick Anger, BS", 
            "phone": "608-262-8649"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Wisconsin, Madison", 
                "last_name": "Steve Howard, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Wisconsin, Madison", 
                "last_name": "H. Ian Robins, MD, Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "time of first dose of PDRD+ Bevacizumab until time of death", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "end of study, which will be an average of 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "time of first dose of PDRD+ Bevacizumab until time of death. All changes from baseline assessment will be recorded until 30 days post last dose of bevacizumab. In addition any late toxicity that is likely attributable to re-irradiation or bevacizumab will be recorded.", 
                "measure": "safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "assessed  every two weeks prior to each bevacizumab infusion while on treatment then 30 post completion of therapy"
            }, 
            {
                "description": "will be determined based on clinical and radiographic evidence", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "at 3months for bevacizumab exposed patients, at 6 and 12 months for all patients"
            }, 
            {
                "description": "will be assessed by physician with mini-mental exam and a FACT BR completed by the patient", 
                "measure": "neurologic changes", 
                "safety_issue": "No", 
                "time_frame": "baseline and then approximately every 8 weeks for 18 months"
            }
        ], 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}